E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Psoriatic arthritis |
Psoriasisarthritis |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10037162 |
E.1.2 | Term | Psoriatic arthropathy |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To describe early and long term central nervous system (CNS) pain response due to blood oxygenation level dependent (BOLD) signal changes in fMRI of the brain to upadacitinib treatment in psoriatic arthritis |
|
E.2.2 | Secondary objectives of the trial |
To identify biomarkers associated with early and long term (CNS) pain response due Blood oxygenation level dependent (BOLD) signal changes in fMRI of the brain to upadacitinib treatment in psoriatic arthritis |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Must understand and voluntarily sign an informed consent form including written consent for data protection Adults aged ≥ 18 years and < 65 years at time of consent Patients fulfilling CASPAR criteria for PsA Subjects must have active hand joint involvement (at least one swollen/tender joint) Indication for systemic treatment Subjects who failed to respond to or are intolerant to at least one csDMARD Subjects who were not exposed to more than one bDMARD before; for bDMARDs the wash-out period should be at least three times the half-life of the bDMARD concerned. Eligibility for the treatment with Upadacitinib according to the EU label Glucocorticoids less than 10mg/day will be allowed Male subjects (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in reproductive sexual activity with Females of Childbearing Potential (FCBP) while on study medication and for at least 28 days after taking the last dose of study medication. Females of childbearing potential (FCBP) must have a negative urine pregnancy test at baseline and must be willing to use one highly-effective form of birth control when engaging in reproductive sexual activity while on study medication and for at least 28 days after taking the last dose of study medication. Must be able to adhere to the study visit schedule and other protocol requirements
|
|
E.4 | Principal exclusion criteria |
- Prior exposure to any Janus kinase (JAK) inhibitor - ANC < 1.000/mm3, ALC < 500/mm3 or hemoglobin < 8g/dl - Any contraindication to perform MRI - Anti-CCP- Antibody positivity - Any other autoimmune or inflammatory disease such as SLE, PSS, MCTD, Behcet`s disease, vasculitis or autoimmune hepatitis. - Malignancy risk factors (e.g. current malignancy or history of malignancy) - Any severe active infection, e.g. hepatitis B or C, SARS-CoV 2 (COVID 19), or active tuberculosis as defined by a positive Quantiferon TB-test. If presence of latent tuberculosis is established then treatment according to local guidelines must have been initiated prior to enrollment. - Have a known history of serious infections (e.g., hepatitis, pneumonia, or pyelonephritis) in the previous 3 months - Immunocompromised patients - Uncontrolled severe concomitant disease - Pregnant or lactating females - Known hypersensitivity to upadacitinib or any other drug components - Requirement for immunization with live vaccine during the trial period or within 4 weeks preceding baseline - History of venous thrombosis or pulmonary embolism, inherited coagulation disorder, planned major surgery, immobilisation - History of atherosclerotic cardiovascular disease or other cardiovascular risk factors - Current or past long-time smokers - Clinically significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, neurologic, gastrointestinal, immunologic, or other major diseases - Evidence of severe renal dysfunction defined as: eGFR < 30 ml/min/1,73 m2 (calculated using the MDRD formula) at screening (Visit 1) - Evidence of severe hepatic insufficiency defined as Child-Pugh score ≥ 10 (C) - Abnormal liver function tests such as GOT (AST), GPT (ALT), alkaline phosphatase or bilirubin. The investigator should be guided by the following criteria: o GOT, GPT, alkaline phosphatase: any single parameter may not exceed 3x upper limit of normal (ULN). A single parameter elevated up to and including 3x ULN should be re-checked once more as soon as possible. o Total bilirubin: if total bilirubin concentration is increased above 2x ULN, total bilirubin should be differentiated into direct and indirect reacting bilirubin. In any case, serum bilirubin should not exceed the value of 1,6mg/dl (exemption: the diagnose of gilbert´s syndrome has already been established or based on higher levels of unconjugated bilirubin without either signs of other liver problems or red blood cell breakdown can be made) - Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study - Patients who are younger than 18 years or are incapable to understand the aim, importance and consequences of the study and to give legal informed consent (according to § 40 Abs. 4 and § 41 Abs. 2 and Abs. 3 AMG). - Have a history of alcohol or substance abuse within the preceding 6 months that, in the opinion of the investigator, may increase the risks associated with study participation or study agent administration, or may interfere with interpretation of results - Patients who possibly are dependent on the Sponsor, the Principal Investigator or Investigator (e.g. family members) - Have participated in this study before with respect to having received upadacitinib. Re-Screening is allowed once
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
BOLD signal voxel count at week 1 and week 12 compared to baseline |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
baseline (BL), week one and week 12 |
|
E.5.2 | Secondary end point(s) |
fMRI: (week 1 and week 12 compared to baseline) - activation size of the BOLD signal (number) at week 1 and week 12 compared to baseline - amplitude of the BOLD signal (number) at week 1 and week 12 compared to baseline - graph-theoretical parameters for all structures along the pain pathway at baseline and week 1 and week 12 - changes in brain anatomy defined as rewiring of brain centers at week 12 compared to baseline.
Clinical evaluation, PROs and Composite outcome measures: - Patient global assessment of pain, Patient global assessment of disease activity, Physician global assessment of disease activity (VAS) - Joint count: 66/68 - DAS28 (CRP) - DAPSA - SPARCC - LEI - MASES - Dactylitis Score - PASI - PSAID - PASDAS - SF 36 - MDA - HAQ-DI - FACIT-Fatigue PATIENT DIARY Ultrasound Synovitis Score of the MCP joints TISSUE EXPLORATIVE SERUM BIOMARKERS |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
BL, week 1, week 4, week 12) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |